EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Biofactories Applied to Future Antivenom Production

Gregorio Juan Mc callum, María Sol Rodriguez, Christian Leandro Macoretta, Ignacio Smith, Federico Javier Wolman, Alexandra Marisa Targovnik, Adolfo Rafael de Roodt, María Victoria Miranda, Matías Fingermann

Journal of Pharmaceutical and BioTech Industry · 07.04.2026 · 3 (2) · 8

DOI: 10.3390/jpbi3020008 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Pharmaceutical and BioTech Industry, online erschienen am 07.04.2026. Verfasst von Gregorio Juan Mc callum und 8 weiteren Autor:innen. Die Arbeit nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Universidad de Buenos Aires, CONICET, Fondo Argentino Sectorial.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Accidents caused by the Loxosceles laeta spider constitute a health problem in South America. Envenomation can lead to severe systemic manifestations, eventually compromising the patient’s life. Most regional health authorities consider antivenom administration the basis of effective treatment in the most serious cases. The availability of spider venom is the primary bottleneck for antivenom production. Herein, we present a novel biotechnological approach, based on the expression of recombinant versions of the most relevant toxin in loxoscelism, sphingomyelinase D (SphD), in insect larvae (Spodoptera frugiperda).

Methods

We produced two versions of SphD: one conserving its biological activities (wtSphD) and a second alternative that was designed to be genetically detoxified (dSphD). Two horses were subjected to three consecutive hyperimmunization cycles with dSphD. The horses’ plasma was extracted at the end of each cycle and used to produce Active Pharmaceutical Ingredients (APIs) of antivenoms at a pilot scale.

Results

Dermonecrotic activity of wtSphD was completely neutralized with the sera obtained from one horse and partially with that of the other. In contrast, the APIs derived in both cases completely neutralized wtSphD dermonecrotic activity. Direct hemolysis of human red blood cells by wtSphD was also neutralized by sera and APIs.

Conclusions

These results show venom replacement or complementation potential by recombinant dSphD produced in this novel platform.

Förderung

  • Universidad de Buenos Aires
  • CONICET
  • Fondo Argentino Sectorial

Zitieren

APA

callum, G. J. M., Rodriguez, M. S., Macoretta, C. L., Smith, I., Wolman, F. J., Targovnik, A. M., Roodt, A. R. D., Miranda, M. V., & Fingermann, M. (2026). Biofactories Applied to Future Antivenom Production. Journal of Pharmaceutical and BioTech Industry, 3(2), 8. https://doi.org/10.3390/jpbi3020008

Vancouver

callum GJM, Rodriguez MS, Macoretta CL, Smith I, Wolman FJ, Targovnik AM, et al. Biofactories Applied to Future Antivenom Production. Journal of Pharmaceutical and BioTech Industry. 2026;3(2):8. doi:10.3390/jpbi3020008

BibTeX
@article{callum2026,
  author = {callum, Gregorio Juan Mc and Rodriguez, María Sol and Macoretta, Christian Leandro and Smith, Ignacio and Wolman, Federico Javier and Targovnik, Alexandra Marisa and Roodt, Adolfo Rafael de and Miranda, María Victoria and Fingermann, Matías},
  title = {Biofactories Applied to Future Antivenom Production},
  journal = {Journal of Pharmaceutical and BioTech Industry},
  year = {2026},
  volume = {3},
  number = {2},
  pages = {8},
  doi = {10.3390/jpbi3020008}
}
Kostenlos starten →